News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actelion Ltd. (ALIOF.PK)'s Drug Approval Seen Enticing Buyers



10/28/2013 8:04:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion Ltd. (ATLN) is once again shaping up as a takeover candidate after the lung-disease drug on which the company staked its future won regulatory approval. The drugmaker, which has a market value of 8.3 billion Swiss francs ($9.3 billion), was granted U.S. approval on Oct. 18 for Opsumit, a pill to treat pulmonary arterial hypertension that may generate $1.1 billion in annual revenue by 2017, according to analysts’ estimates compiled by Bloomberg.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES